Latest News

Date Title Topic
17 Feb 2016 Investing in the US National Cancer Moonshot Bioethics, legal and economic issues
15 Feb 2016 How to Facilitate Development of Cancer Immunotherapies Bioethics, legal and economic issues - Cancer Immunology and Immunotherapy
15 Feb 2016 FDA Grants Breakthrough Therapy Designation for Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma Sarcomas - Cancer Immunology and Immunotherapy
11 Feb 2016 FDA Grants Breakthrough Therapy Designation for Sacituzumab Govitecan for the Treatment of TNBC Breast cancer - Cancer Immunology and Immunotherapy
10 Feb 2016 Academic Research in Breast Cancer Breast cancer
08 Feb 2016 Exploring the Growing Interest in Drug Repurposing in Oncology Bioethics, legal and economic issues
04 Feb 2016 ESMO Press Release: World Cancer Day 2016 – ESMO and Patient Advocates, Together to Support Research Bioethics, legal and economic issues
04 Feb 2016 ESMO Supports World Cancer Day 2016 Bioethics, legal and economic issues
04 Feb 2016 EMA Adopts a New Indication for Lenalidomide Haematologic malignancies - Anticancer agents & Biologic therapy
03 Feb 2016 Reshaping the Cancer Clinic Personalised medicine
07 Apr 2016 ESMO Preceptorship on Immuno-Oncology 2016: Siena
02 Feb 2016 ESMO Press Release: Keith Hanson McGregor Appointed New ESMO CEO
02 Feb 2016 FDA Approves Eribulin Mesylate for the Treatment of Unresectable or Advanced Liposarcoma Sarcomas - Anticancer agents & Biologic therapy
01 Feb 2016 EMA Recommends Granting a Marketing Authorisation for Elotuzumab Haematologic malignancies - Anticancer agents & Biologic therapy